Science & Research

Dr. Eliaz and his team partner with renowned institutes including Harvard, Columbia, and others to investigate integrative approaches in the treatment of cancer and chronic conditions. In addition, many of Dr. Eliaz’s unique preparations have been studied independently by third-party groups, with peer-reviewed results demonstrating unparalleled benefits against cancer, fibrotic diseases and more.

The unique form of Modified Citrus Pectin developed by Dr. Eliaz is recognized as the only commercially available galectin-3 blocker, substantiated by more than 75+ published studies in cancer, cardiovascular disease, chronic kidney disease, and other pro-inflammatory, degenerative conditions.

Summaries with links to research abstracts

Breast Cancer Research

2017 Preclinical Study: Polybotanical Breast Formula Enhances Tamoxifen in Estrogen Receptor-Positive Human Breast Cancer In Vitro and In Vivo 2012 Preclinical Study: Breast Formula Prevents Read More »

Read More

Galectin-3 Research

2021 Translational Study: Galectin-3 in septic acute kidney injury: a translational study 2021 Preclinical Study: Galectin-3 participates in PASMC migration and proliferation by interacting with Read More »

Read More

Honokiol Research

2020 Preclinical Study: Honokiol Ameliorates Pulmonary Fibrosis 2020 Preclinical Study: Honokiol Inhibits Melanoma Growth 2019 Preclinical Study: Antidepressant-like Effects of Honokiol 2019 Review: Anticancer Potential Read More »

Read More

Prostate Cancer Research

2019 Clinical Study Updated Results: Modified Citrus Pectin Halts Biochemically-Relapsed Prostate Cancer 2018 Clinical Survey: Polybotanical Prostate Formula Shows Improvements in Lower Urinary Tract Symptoms Read More »

Read More
Accessibility Tools